Oncology Products and Development Excellence committed to the rapid, precise and efficient introduction of innovative therapeutic products that cancer patients urgently need now. 

Copyright © Ascalon International 2009
All Rights Reserved
"Excellence in Commercial Oncology Drug Development"

Ascalon News:
Feb 24, 2011  Ascalon to present at National Venture Capital and Angel Investor Forum (Yale Club) in New York City

Feb  17, 2011 Fenretinide awarded $500K grant by NCI to support further phase I combination development work. The application was considered amongst the top 1% of all submissions put in to the Clinical Oncology Study Section requesting funding for new oncology trials.